{"pmid":32411619,"pmcid":"PMC7202255","title":"Current and Future Point-of-Care Tests for Emerging and New Respiratory Viruses and Future Perspectives.","text":["Current and Future Point-of-Care Tests for Emerging and New Respiratory Viruses and Future Perspectives.","The availability of pathogen-specific treatment options for respiratory tract infections (RTIs) increased the need for rapid diagnostic tests. Besides, retrospective studies, improved lab-based detection methods and the intensified search for new viruses since the beginning of the twenty-first century led to the discovery of several novel respiratory viruses. Among them are human bocavirus (HBoV), human coronaviruses (HCoV-HKU1, -NL63), human metapneumovirus (HMPV), rhinovirus type C (RV-C), and human polyomaviruses (KIPyV, WUPyV). Additionally, new viruses like SARS coronavirus (SARS-CoV), MERS coronavirus (MERS-CoV), novel strains of influenza virus A and B, and (most recently) SARS coronavirus 2 (SARS-CoV-2) have emerged. Although clinical presentation may be similar among different viruses, associated symptoms may range from a mild cold to a severe respiratory illness, and thus require a fast and reliable diagnosis. The increasing number of commercially available rapid point-of-care tests (POCTs) for respiratory viruses illustrates both the need for this kind of tests but also the problem, i.e., that the majority of such assays has significant limitations. In this review, we summarize recently published characteristics of POCTs and discuss their implications for the treatment of RTIs. The second key aspect of this work is a description of new and innovative diagnostic techniques, ranging from biosensors to novel portable and current lab-based nucleic acid amplification methods with the potential future use in point-of-care settings. While prototypes for some methods already exist, other ideas are still experimental, but all of them give an outlook of what can be expected as the next generation of POCTs.","Front Cell Infect Microbiol","Nelson, Philipp P","Rath, Barbara A","Fragkou, Paraskevi C","Antalis, Emmanouil","Tsiodras, Sotirios","Skevaki, Chrysanthi","32411619"],"abstract":["The availability of pathogen-specific treatment options for respiratory tract infections (RTIs) increased the need for rapid diagnostic tests. Besides, retrospective studies, improved lab-based detection methods and the intensified search for new viruses since the beginning of the twenty-first century led to the discovery of several novel respiratory viruses. Among them are human bocavirus (HBoV), human coronaviruses (HCoV-HKU1, -NL63), human metapneumovirus (HMPV), rhinovirus type C (RV-C), and human polyomaviruses (KIPyV, WUPyV). Additionally, new viruses like SARS coronavirus (SARS-CoV), MERS coronavirus (MERS-CoV), novel strains of influenza virus A and B, and (most recently) SARS coronavirus 2 (SARS-CoV-2) have emerged. Although clinical presentation may be similar among different viruses, associated symptoms may range from a mild cold to a severe respiratory illness, and thus require a fast and reliable diagnosis. The increasing number of commercially available rapid point-of-care tests (POCTs) for respiratory viruses illustrates both the need for this kind of tests but also the problem, i.e., that the majority of such assays has significant limitations. In this review, we summarize recently published characteristics of POCTs and discuss their implications for the treatment of RTIs. The second key aspect of this work is a description of new and innovative diagnostic techniques, ranging from biosensors to novel portable and current lab-based nucleic acid amplification methods with the potential future use in point-of-care settings. While prototypes for some methods already exist, other ideas are still experimental, but all of them give an outlook of what can be expected as the next generation of POCTs."],"journal":"Front Cell Infect Microbiol","authors":["Nelson, Philipp P","Rath, Barbara A","Fragkou, Paraskevi C","Antalis, Emmanouil","Tsiodras, Sotirios","Skevaki, Chrysanthi"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32411619","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3389/fcimb.2020.00181","keywords":["poct","bedside testing","biosensors","commercial point-of-care tests","innovative approaches","virus diagnostics"],"topics":["Diagnosis"],"weight":1,"_version_":1666897319215235073,"score":9.490897,"similar":[{"pmid":32196430,"pmcid":"PMC7172701","title":"Laboratory diagnosis of emerging human coronavirus infections - the state of the art.","text":["Laboratory diagnosis of emerging human coronavirus infections - the state of the art.","The three unprecedented outbreaks of emerging human coronavirus (HCoV) infections at the beginning of the twenty-first century have highlighted the necessity for readily available, accurate and fast diagnostic testing methods. The laboratory diagnostic methods for human coronavirus infections have evolved substantially, with the development of novel assays as well as the availability of updated tests for emerging ones. Newer laboratory methods are fast, highly sensitive and specific, and are gradually replacing the conventional gold standards. This presentation reviews the current laboratory methods available for testing coronaviruses by focusing on the coronavirus disease 2019 (COVID-19) outbreak going on in Wuhan. Viral pneumonias typically do not result in the production of purulent sputum. Thus, a nasopharyngeal swab is usually the collection method used to obtain a specimen for testing. Nasopharyngeal specimens may miss some infections; a deeper specimen may need to be obtained by bronchoscopy. Alternatively, repeated testing can be used because over time, the likelihood of the SARS-CoV-2 being present in the nasopharynx increases. Several integrated, random-access, point-of-care molecular devices are currently under development for fast and accurate diagnosis of SARS-CoV-2 infections. These assays are simple, fast and safe and can be used in the local hospitals and clinics bearing the burden of identifying and treating patients.","Emerg Microbes Infect","Loeffelholz, Michael J","Tang, Yi-Wei","32196430"],"abstract":["The three unprecedented outbreaks of emerging human coronavirus (HCoV) infections at the beginning of the twenty-first century have highlighted the necessity for readily available, accurate and fast diagnostic testing methods. The laboratory diagnostic methods for human coronavirus infections have evolved substantially, with the development of novel assays as well as the availability of updated tests for emerging ones. Newer laboratory methods are fast, highly sensitive and specific, and are gradually replacing the conventional gold standards. This presentation reviews the current laboratory methods available for testing coronaviruses by focusing on the coronavirus disease 2019 (COVID-19) outbreak going on in Wuhan. Viral pneumonias typically do not result in the production of purulent sputum. Thus, a nasopharyngeal swab is usually the collection method used to obtain a specimen for testing. Nasopharyngeal specimens may miss some infections; a deeper specimen may need to be obtained by bronchoscopy. Alternatively, repeated testing can be used because over time, the likelihood of the SARS-CoV-2 being present in the nasopharynx increases. Several integrated, random-access, point-of-care molecular devices are currently under development for fast and accurate diagnosis of SARS-CoV-2 infections. These assays are simple, fast and safe and can be used in the local hospitals and clinics bearing the burden of identifying and treating patients."],"journal":"Emerg Microbes Infect","authors":["Loeffelholz, Michael J","Tang, Yi-Wei"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32196430","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1080/22221751.2020.1745095","keywords":["covid-19","human coronavirus","poct","sars-cov-2","real-time pcr","serology"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138490038910978,"score":204.18349},{"pmid":32293743,"title":"Coinfection with COVID-19 and Coronavirus HKU1 - the critical need for repeat testing if clinically indicated.","text":["Coinfection with COVID-19 and Coronavirus HKU1 - the critical need for repeat testing if clinically indicated.","COVID-19 is the latest global pandemic caused by severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2). There have been seven pathogenic Human Coronaviruses (HCoVs) which cause respiratory infections. Common cold coronaviruses HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1 are the four endemic HCoVs. SARS-CoV-1, MERS-CoV, SARS-CoV-2 are zoonotic emerging epidemic pathogens with significant morbidity, mortality and economic impact. The endemic HCoVs have been known to cause co-infections or can be co-detected with each other or with other respiratory viruses. In general, respiratory viral co-infections are recognized more commonly today with the use of respiratory multiplex molecular diagnostic panels. Clinicians need to be aware of co-infections among HCoVs. A high degree of suspicion in this rapidly evolving outbreak is required in order to make the diagnosis. This is vital if we are to try and contain and control the spread of the COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Chaung, Jenna","Chan, Douglas","Pada, Surinder","Tambyah, Paul A","32293743"],"abstract":["COVID-19 is the latest global pandemic caused by severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2). There have been seven pathogenic Human Coronaviruses (HCoVs) which cause respiratory infections. Common cold coronaviruses HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1 are the four endemic HCoVs. SARS-CoV-1, MERS-CoV, SARS-CoV-2 are zoonotic emerging epidemic pathogens with significant morbidity, mortality and economic impact. The endemic HCoVs have been known to cause co-infections or can be co-detected with each other or with other respiratory viruses. In general, respiratory viral co-infections are recognized more commonly today with the use of respiratory multiplex molecular diagnostic panels. Clinicians need to be aware of co-infections among HCoVs. A high degree of suspicion in this rapidly evolving outbreak is required in order to make the diagnosis. This is vital if we are to try and contain and control the spread of the COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chaung, Jenna","Chan, Douglas","Pada, Surinder","Tambyah, Paul A"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293743","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25890","keywords":["coronavirus","infection","sars coronavirus","virus classification"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494338072577,"score":197.98396},{"pmid":32293832,"pmcid":"PMC7195990","title":"Coronaviruses and SARS-COV-2","text":["Coronaviruses and SARS-COV-2","Coronaviruses (CoVs) cause a broad spectrum of diseases in domestic and wild animals, poultry, and rodents, ranging from mild to severe enteric, respiratory, and systemic disease, and also cause the common cold or pneumonia in humans. Seven coronavirus species are known to cause human infection, 4 of which, HCoV 229E, HCoV NL63, HCoV HKU1 and HCoV OC43, typically cause cold symptoms in immunocompetent individuals. The others namely SARS-CoV (severe acute respiratory syndrome coronavirus), MERS-CoV (Middle East respiratory syndrome coronavirus) were zoonotic in origin and cause severe respiratory illness and fatalities. On 31 December 2019, the existence of patients with pneumonia of an unknown aetiology was reported to WHO by the national authorities in China. This virus was officially identified by the coronavirus study group as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the present outbreak of a coronavirus-associated acute respiratory disease was labelled coronavirus disease 19 (COVID-19). COVID-19's first cases were seen in Turkey on March 10, 2020 and was number 47,029 cases and 1006 deaths after 1 month. Infections with SARS-CoV-2 are now widespread, and as of 10 April 2020, 1,727,602 cases have been confirmed in more than 210 countries, with 105,728 deaths.","Turk J Med Sci","Hasoksuz, Mustafa","Kilic, Selcuk","Sarac, Fahriye","32293832"],"abstract":["Coronaviruses (CoVs) cause a broad spectrum of diseases in domestic and wild animals, poultry, and rodents, ranging from mild to severe enteric, respiratory, and systemic disease, and also cause the common cold or pneumonia in humans. Seven coronavirus species are known to cause human infection, 4 of which, HCoV 229E, HCoV NL63, HCoV HKU1 and HCoV OC43, typically cause cold symptoms in immunocompetent individuals. The others namely SARS-CoV (severe acute respiratory syndrome coronavirus), MERS-CoV (Middle East respiratory syndrome coronavirus) were zoonotic in origin and cause severe respiratory illness and fatalities. On 31 December 2019, the existence of patients with pneumonia of an unknown aetiology was reported to WHO by the national authorities in China. This virus was officially identified by the coronavirus study group as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the present outbreak of a coronavirus-associated acute respiratory disease was labelled coronavirus disease 19 (COVID-19). COVID-19's first cases were seen in Turkey on March 10, 2020 and was number 47,029 cases and 1006 deaths after 1 month. Infections with SARS-CoV-2 are now widespread, and as of 10 April 2020, 1,727,602 cases have been confirmed in more than 210 countries, with 105,728 deaths."],"journal":"Turk J Med Sci","authors":["Hasoksuz, Mustafa","Kilic, Selcuk","Sarac, Fahriye"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293832","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.3906/sag-2004-127","keywords":["covid-19","sars-cov-2","human coronaviruses","animal coronaviruses","history of coronaviruses"],"locations":["China","Turkey"],"countries":["China","Turkey"],"countries_codes":["CHN|China","TUR|Turkey"],"weight":0,"_version_":1666138494335975424,"score":180.59691},{"pmid":31944312,"pmcid":"PMC7166954","title":"Recent advances in the detection of respiratory virus infection in humans.","text":["Recent advances in the detection of respiratory virus infection in humans.","Respiratory tract viral infection caused by viruses or bacteria is one of the most common diseases in human worldwide, while those caused by emerging viruses, such as the novel coronavirus, 2019-nCoV that caused the pneumonia outbreak in Wuhan, China most recently, have posed great threats to global public health. Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics. Conventional diagnostic tests, such as the assays for rapid detection of antiviral antibodies or viral antigens, are widely used in many clinical laboratories. With the development of modern technologies, new diagnostic strategies, including multiplex nucleic acid amplification and microarray-based assays, are emerging. This review summarizes currently available and novel emerging diagnostic methods for the detection of common respiratory viruses, such as influenza virus, human respiratory syncytial virus, coronavirus, human adenovirus, and human rhinovirus. Multiplex assays for simultaneous detection of multiple respiratory viruses are also described. It is anticipated that such data will assist researchers and clinicians to develop appropriate diagnostic strategies for timely and effective detection of respiratory virus infections.","J Med Virol","Zhang, Naru","Wang, Lili","Deng, Xiaoqian","Liang, Ruiying","Su, Meng","He, Chen","Hu, Lanfang","Su, Yudan","Ren, Jing","Yu, Fei","Du, Lanying","Jiang, Shibo","31944312"],"abstract":["Respiratory tract viral infection caused by viruses or bacteria is one of the most common diseases in human worldwide, while those caused by emerging viruses, such as the novel coronavirus, 2019-nCoV that caused the pneumonia outbreak in Wuhan, China most recently, have posed great threats to global public health. Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics. Conventional diagnostic tests, such as the assays for rapid detection of antiviral antibodies or viral antigens, are widely used in many clinical laboratories. With the development of modern technologies, new diagnostic strategies, including multiplex nucleic acid amplification and microarray-based assays, are emerging. This review summarizes currently available and novel emerging diagnostic methods for the detection of common respiratory viruses, such as influenza virus, human respiratory syncytial virus, coronavirus, human adenovirus, and human rhinovirus. Multiplex assays for simultaneous detection of multiple respiratory viruses are also described. It is anticipated that such data will assist researchers and clinicians to develop appropriate diagnostic strategies for timely and effective detection of respiratory virus infections."],"journal":"J Med Virol","authors":["Zhang, Naru","Wang, Lili","Deng, Xiaoqian","Liang, Ruiying","Su, Meng","He, Chen","Hu, Lanfang","Su, Yudan","Ren, Jing","Yu, Fei","Du, Lanying","Jiang, Shibo"],"date":"2020-01-17T11:00:00Z","year":2020,"_id":"31944312","source":"PubMed","week":"20203|Jan 13 - Jan 19","doi":"10.1002/jmv.25674","keywords":["adenovirus","coronavirus","diagnostic methods","influenza virus","respiratory syncytial virus","respiratory viral infection","rhinovirus"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493078732800,"score":177.75273},{"pmid":32306853,"title":"Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2.","text":["Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2.","The previous outbreaks of SARS-CoV and MERS-CoV have led researchers to study the role of diagnostics in impediment of further spread and transmission. With the recent emergence of the novel SARS-CoV-2, the availability of rapid, sensitive, and reliable diagnostic methods is essential for disease control. Hence, we have developed a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for the specific detection of SARS-CoV-2. The primer sets for RT-LAMP assay were designed to target the nucleocapsid gene of the viral RNA, and displayed a detection limit of 10(2) RNA copies close to that of qRT-PCR. Notably, the assay has exhibited a rapid detection span of 30 min combined with the colorimetric visualization. This test can detect specifically viral RNAs of the SARS-CoV-2 with no cross-reactivity to related coronaviruses, such as HCoV-229E, HCoV-NL63, HCoV-OC43, and MERS-CoV as well as human infectious influenza viruses (type B, H1N1pdm, H3N2, H5N1, H5N6, H5N8, and H7N9), and other respiratory disease-causing viruses (RSVA, RSVB, ADV, PIV, MPV, and HRV). Furthermore, the developed RT-LAMP assay has been evaluated using specimens collected from COVID-19 patients that exhibited high agreement to the qRT-PCR. Our RT-LAMP assay is simple to perform, less expensive, time-efficient, and can be used in clinical laboratories for preliminary detection of SARS-CoV-2 in suspected patients. In addition to the high sensitivity and specificity, this isothermal amplification conjugated with a single-tube colorimetric detection method may contribute to the public health responses and disease control, especially in the areas with limited laboratory capacities.","Emerg Microbes Infect","Baek, Yun Hee","Um, Jihye","Antigua, Khristine Joy C","Park, Ji-Hyun","Kim, Yeonjae","Oh, Sol","Kim, Young-Il","Choi, Won-Suk","Kim, Seong Gyu","Jeong, Ju Hwan","Chin, Bum Sik","Nicolas, Halcyon Dawn G","Ahn, Ji-Young","Shin, Kyeong Seob","Choi, Young Ki","Park, Jun-Sun","Song, Min-Suk","32306853"],"abstract":["The previous outbreaks of SARS-CoV and MERS-CoV have led researchers to study the role of diagnostics in impediment of further spread and transmission. With the recent emergence of the novel SARS-CoV-2, the availability of rapid, sensitive, and reliable diagnostic methods is essential for disease control. Hence, we have developed a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for the specific detection of SARS-CoV-2. The primer sets for RT-LAMP assay were designed to target the nucleocapsid gene of the viral RNA, and displayed a detection limit of 10(2) RNA copies close to that of qRT-PCR. Notably, the assay has exhibited a rapid detection span of 30 min combined with the colorimetric visualization. This test can detect specifically viral RNAs of the SARS-CoV-2 with no cross-reactivity to related coronaviruses, such as HCoV-229E, HCoV-NL63, HCoV-OC43, and MERS-CoV as well as human infectious influenza viruses (type B, H1N1pdm, H3N2, H5N1, H5N6, H5N8, and H7N9), and other respiratory disease-causing viruses (RSVA, RSVB, ADV, PIV, MPV, and HRV). Furthermore, the developed RT-LAMP assay has been evaluated using specimens collected from COVID-19 patients that exhibited high agreement to the qRT-PCR. Our RT-LAMP assay is simple to perform, less expensive, time-efficient, and can be used in clinical laboratories for preliminary detection of SARS-CoV-2 in suspected patients. In addition to the high sensitivity and specificity, this isothermal amplification conjugated with a single-tube colorimetric detection method may contribute to the public health responses and disease control, especially in the areas with limited laboratory capacities."],"journal":"Emerg Microbes Infect","authors":["Baek, Yun Hee","Um, Jihye","Antigua, Khristine Joy C","Park, Ji-Hyun","Kim, Yeonjae","Oh, Sol","Kim, Young-Il","Choi, Won-Suk","Kim, Seong Gyu","Jeong, Ju Hwan","Chin, Bum Sik","Nicolas, Halcyon Dawn G","Ahn, Ji-Young","Shin, Kyeong Seob","Choi, Young Ki","Park, Jun-Sun","Song, Min-Suk"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32306853","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1080/22221751.2020.1756698","keywords":["covid-19","sars-cov-2","colorimetric detection","molecular diagnosis","novel coronavirus","reverse transcription-loop-mediated isothermal amplification"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491234287617,"score":174.81128}]}